Should you buy Amgen stock now?
Yes, the technical signal for Amgen is currently Buy. Amgen trades at $402.60 as of Oct 7, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 0.289 with rising momentum (signal: -0.047); RSI is at 47.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $390.94 is 2.9% below the current price. This is a technical observation based on current data, not investment advice.
What is the price target for Amgen stock?
The average analyst price target for Amgen is $390.94. The current price is $402.60, which gives a downside of 2.9%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $351.85 and $430.03.
Is Amgen a dividend stock?
Yes, Amgen is a dividend stock with a dividend yield of 2.41%. The latest dividend was $2.52 per share. The latest ex-dividend date (traded without the dividend) was Aug 21, 2026. The payout ratio is 44.4%, which is considered sustainable.
When does Amgen pay a dividend in 2026?
The next dividend date for Amgen has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was Aug 21, 2026. The latest dividend was $2.52 per share with an ex-dividend date of Aug 21, 2026. The dividend yield is 2.41%. The payout ratio of 44.4% points to a sustainable dividend with room to grow.
What is the risk of Amgen stock?
Amgen is rated as a stock in the risk category Balanced. the annual standard deviation is 29.1%, which classifies the stock as Balanced.
Is Amgen overvalued?
Amgen is considered fairly valued – the price is close to the analyst price target. Amgen has the following valuation ratios: a P/E ratio of 25.1 (moderately to highly valued), a P/S ratio of 5.7, a P/B ratio of 18.8. The stock trades close to the analyst price target and is considered fairly valued.
Is Amgen overbought?
No, Amgen is not overbought. RSI is at 47.6 (neutral zone). The technical indicators show: RSI is at 47.6 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.2% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Amgen earnings report?
Amgen reports its next earnings on November 3, 2026. The stock currently trades at $402.60. With a P/E ratio of 25.1, the market will be watching closely whether earnings meet expectations.
Is Amgen shorted?
Yes, Amgen is shorted with 2.6% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Amgen stock?
No, insiders are not buying Amgen shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 4 sales. On a net basis, 2,971,621 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 39,097,009 $ sold. Active sellers include Khosla Rachna, Miller Derek, Grygiel Nancy A. and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Amgen a good stock?
Based on our total score, Amgen is rated as a good stock with a total score of 64 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 32/100, Quality: 89/100, Momentum: 72/100. In addition: a dividend of 2.41%; technical signal: Buy. Whether Amgen is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Amgen stock?
The outlook for Amgen based on current data: the average analyst price target is $390.94 (-2.9%); the next earnings report is due on Nov 3, 2026, which can move the price; the P/E ratio is 25.1 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Amgen stock moving?
Amgen is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Amgen go?
The average analyst price target for Amgen is $390.94, which is 2.9% below the current price of $402.60. The stock has traded between $280.23 and $447.03 over the last 52 weeks. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Amgen fall?
The stock has traded as low as $280.23 over the last 52 weeks — that is 30.4% below the current price of $402.60. The biggest decline (drawdown) in the same period was 37.3% from high to low. Within a year, the price typically swings about ±29.1% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Amgen do?
Amgen makes and sells medicine around the world. The company discovers, develops and manufactures treatments for people with serious illnesses, especially in the areas of inflammation, cancer, heart and blood vessel diseases, and bone health. Amgen makes most of its money by s... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Amgen as an investment.
Did Amgen raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Amgen. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Amgen making money or losing money?
Yes, Amgen is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 23.0% — which is excellent. The operating margin (profit before interest and taxes) is 35.6%. At a P/E ratio of 25.1, you currently pay 25.1 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Amgen go bankrupt?
The bankruptcy risk of Amgen is rated as elevated. Altman Z2 (a model for assessing financial distress) is 0.95 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 8 — which is strong. Debt relative to equity is 1,463% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Amgen have a lot of debt?
Yes, Amgen has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,463%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Amgen service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 5.1x, and net debt equals 2.5 years of earnings (EBITDA).
